According to Taysha Gene Therapies's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 31.2282. At the end of 2023 the company had a P/S ratio of 21.4.
Year | P/S ratio | Change |
---|---|---|
2023 | 21.4 | -62.03% |
2022 | 56.4 | |
2021 | N/A | |
2020 | N/A |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
ORIC Pharmaceuticals
ORIC | N/A | N/A | ๐บ๐ธ USA |